DiaMedica Therapeutics, Inc.
(NASDAQ : DMAC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-2.13%199.081.3%$749.78m
GILDGilead Sciences, Inc.
-2.66%62.510.9%$372.82m
CELGCelgene Corporation
-1.80%93.991.3%$323.19m
ALXNAlexion Pharmaceuticals, Inc.
-6.61%115.332.0%$295.67m
ILMNIllumina, Inc.
-3.17%279.443.5%$272.03m
BIIBBiogen Inc.
-2.68%225.851.3%$258.17m
VRTXVertex Pharmaceuticals Incorporated
-2.20%180.181.9%$251.48m
EXASExact Sciences Corporation
-0.77%116.9624.1%$238.08m
REGNRegeneron Pharmaceuticals, Inc.
-2.77%286.852.6%$193.57m
AAgilent Technologies, Inc.
-3.01%69.581.6%$188.95m
SRPTSarepta Therapeutics, Inc.
-1.54%93.6114.7%$184.96m
BMRNBioMarin Pharmaceutical Inc.
-2.12%75.764.3%$97.12m
INCYIncyte Corporation
-4.27%81.912.5%$90.56m
GHDXGenomic Health, Inc.
-0.35%73.261.8%$81.69m
NBIXNeurocrine Biosciences, Inc.
0.36%97.595.0%$71.75m

Company Profile

DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.